Safety Issues for Plasma Derivatives and Benefit from NAT Testing
- 31 December 1999
- journal article
- Published by Elsevier in Biologicals
- Vol. 27 (4) , 325-331
- https://doi.org/10.1006/biol.1999.0227
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Parvovirus B19 DNA Contamination in Coagulation Factor VIII ProductsThrombosis and Haemostasis, 1999
- Presence and Significance of Parvovirus B19 in Blood and Blood ProductsBiologicals, 1998
- A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia AThrombosis and Haemostasis, 1997
- Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilizationTransfusion, 1997
- The Prevalence of Antibody to Parvovirus B19 in Hemophiliacs and in the General PopulationZentralblatt für Bakteriologie, 1996
- Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 1996
- Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 1996
- Life-threatening human parvovirus B19 infection in immunocompetent haemophiliaThe Lancet, 1995
- B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 1994
- Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 1992